C4 Therapeutics, Inc. Income Statement
CCCC|4 years of annual SEC 10-K data (FY2022-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 4 fiscal years. All figures from audited SEC 10-K filings.
C4 Therapeutics, Inc. reported $36M in revenue and $105M in net loss for FY2025. Revenue has declined at a 7.7% compound annual rate over the past 3 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -1.14 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $35.9M | $20.8M | $20.8M | $45.8M |
| SG&A Expense | $36.2M | $42.1M | $42.1M | $33.3M |
| R&D Expense | $104.2M | $117.7M | $117.7M | $94.7M |
| Operating Income | -$115.2M | -$139.0M | -$139.0M | -$82.1M |
| Income Tax | $121.0K | $1.3M | $1.3M | $0 |
| Net Income | -$105.0M | -$132.5M | -$132.5M | -$83.9M |
| EPS (Basic) | -$1.52 | -$2.67 | -$2.62 | -$1.82 |
| EPS (Diluted) | -$1.52 | -$2.67 | -$2.62 | -$1.82 |
| Shares Outstanding | 70.6M | 60.5M | 49.0M | 48.7M |
| Operating Margin | -320.5% | -669.8% | -669.8% | -179.4% |
| Profit Margin | -292.1% | -638.3% | -638.3% | -183.2% |